百灵毓秀

Bailing Yuxiu is a clinical-stage biotechnology company based in Beijing and a core subsidiary of Keymed Biosciences. The company specializes in the discovery and development of innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), primarily targeting oncology and autoimmune indications. Its lead asset, Stapokibart (CM310), is an IL-4Rα antagonist in Phase 3 development for atopic dermatitis and other allergic diseases. Another key program, CMG901, is a first-in-class Claudin 18.2-targeting ADC that has been out-licensed to AstraZeneca for global development. Bailing Yuxiu leverages its proprietary nCOne and nCpair platforms to generate a robust pipeline of differentiated therapeutic candidates designed to address significant unmet medical needs.